Cystic fibrosis (CF)-associated liver disease (CFLD) is a hepatobiliary complication of CF. Current diagnostic modalities rely on nonspecific assessments, whereas liver biopsy is the gold standard to assess severity of fibrosis. MicroRNAs (miRNAs) regulate liver disease pathogenesis and are proposed as diagnostic biomarkers. We investigated the combined use of serum miRNAs and aspartate aminotransferase (AST) to platelet ratio (APRI) to diagnose and assess CFLD severity. This was a cross-sectional cohort study of the circulatory miRNA signature of 124 children grouped by clinical, biochemical, and imaging assessments as follows: CFLD (n = 44), CF patients with no evidence of liver disease (CFnoLD; n = 40), and healthy controls (n = 40). Serum miRNAs were analyzed using miRNA sequencing (miRNA-Seq). Selected differentially expressed serum miRNA candidates were further validated by qRT-PCR and statistical analysis performed to evaluate utility to predict CFLD and fibrosis severity validated by liver biopsy, alone or in combination with APRI. Serum miR-122-5p, miR-365a-3p, and miR-34a-5p levels were elevated in CFLD compared to CFnoLD, whereas miR-142-3p and let-7g-5p were down-regulated in CFLD compared to CFnoLD. Logistic regression analysis combining miR-365a-3p, miR-142-3p, and let-7g-5p with APRI showed 21 times greater odds of accurately predicting liver disease in CF with an area under the receiver operating characteristics curve (AUROC) = 0.91 (sensitivity = 83%, specificity = 92%; P < 0.0001). Expression levels of serum miR-18a-5p were correlated with increasing hepatic fibrosis (HF) stage in CFLD (r s = 0.56; P < 0.0001), showing good diagnostic accuracy for distinguishing severe (F3-F4) from mild/moderate fibrosis (F0-F2). A unit increase of miR-18a-5p showed a 7-fold increased odds of having severe fibrosis with an AUROC = 0.82 (sensitivity = 93%, specificity = 73%; P = 0.004), indicating its potential to predict fibrosis severity. Conclusion: We identified a distinct circulatory miRNA profile in pediatric CFLD with potential to accurately discriminate liver disease and fibrosis severity in children with CF. (Hepatology 2018;68:2301-2316).
C ystic fibrosis (CF)-associated liver disease (CFLD) is the leading cause of nonrespiratory mortality and morbidity associated with CF.
Abnormal cystic fibrosis transmembrane conductance regulator (CFTR) is proposed to lead to inspissation of viscid bile in the biliary tree, followed by biliary obstruction, hepatocyte and cholangiocyte injury, and periductal inflammation resulting in fibrosis and cirrhosis.
(1) During the recent decades, median life span of patients with CF has dramatically improved as a result of improved respiratory and microbial management and is expected to exceed 50 years of age in patients born after the year 2000. (2) Furthermore, with the advent of CFTR modulators and anticipated life expectancy of 70 years of age by some estimates, (3) vigilant monitoring of nonpulmonary complications such as CFLD is paramount.
According to the World Health Organization, CF affects 1 of 2,500 newborns, (4) 15.6% of whom are eventually diagnosed with clinically significant liver abnormalities and, before the advent of transplantation, was responsible for the death of up to 5% attributed to end-stage liver disease. (5) The true prevalence of CFLD, however, could be as high as 70% based on autopsy studies. (6) The true impact of CFLD on mortality has been underestimated as demonstrated by Lewindon et al. and Rowland et al., who report increased all-cause, childhood mortality in those with CFLD. (7, 8) The diagnosis of CFLD before the advancement of cirrhosis and portal hypertension is challenging. Liver biopsy is not widely popular given that it is invasive, and management pathways are not well elucidated. Alone, it may be unreliable given sampling limitations and the known focal distribution of CFLD lesions; however, it is considered the gold standard to assess severity of liver damage in CFLD. (7) Putative biomarkers of CFLD have focused on biological and physical properties to indirectly assess degree of fibrosis in the liver. Studies have shown increased expression of tissue inhibitor metalloproteinase 4 and endoglin in serum of adult CFLD patients, (9) whereas the aspartate aminotransferase (AST) to platelet ratio index (APRI) and the Fibrosis-4 (FIB-4) index have shown value as biomarkers for the diagnosis and severity of CFLD in children. (10) Other noninvasive alternatives to liver biopsy, such as imaging-based transient elastography, have been used to indirectly assess liver fibrosis (LF) through measurement of liver stiffness, which increases with the progression of fibrosis and cirrhosis. However, the value of elastography in the detection/prediction and monitoring of liver disease and fibrosis in CF has not been fully established, primarily because of the lack of liver biopsy-validated CFLD patients in these studies. (11) (12) (13) MicroRNAs (miRNAs) are short interfering RNAs that silence gene expression at a posttranscriptional level. Altered miRNA expression has been associated with a broader fibrogenic response or liver damage. (14) Furthermore, miRNAs are accessible in body fluids, disease and tissue specific, and stable in the circulation, suggesting their potential utility as biomarkers of disease. (15) Despite the increasing number of studies investigating the use of miRNAs as biomarkers for chronic liver disease (CLD), only a few have been conducted in pediatric liver diseases (reviewed elsewhere (16) ), and only one study, using a limited miRNA PCR array, has focused on CFLD. (17) We hypothesized that there is an alteration in the circulating miRNA signature of children with CFLD that can be used to diagnose liver disease and assess the progression of fibrosis severity among the CF population. We have used next-generation sequencing (NGS) to study differentially expressed serum miRNAs in children with liver-biopsy-validated CFLD versus children with CF without evidence of liver disease (CFnoLD) and healthy controls. Selected miRNA candidates were then validated by qRT-PCR in an extended patient cohort.
Patients and Methods

patieNtS
This study was approved by the human research ethics committees of the QIMR Berghofer Medical Research Institute (Brisbane, Australia) and the Lady Cilento's Children Hospital (Brisbane, Australia). Enrollment of patients and sample collection were conducted between 1997 and 2016. Parental informed consent was obtained for every patient before the start of the study. Sera from 124 well-characterized children were selected and allocated in one of three study cohorts as described: Children with CFLD (n = 44) were selected by the presence of at least two of the following signs or symptoms: hepatomegaly ± splenomegaly; persistent elevation (>6 months) of serum alanine aminotransferase (ALT; >1× upper limit of normal) and abnormal ultrasound scan (showing abnormal echogenicity or nodularity suggesting cirrhosis), as has been described. (6, 7, 18) All patients had percutaneous dual-pass liver biopsies to assess CFLD and stage LF, as described. (7) Liver histology was staged for hepatic fibrosis (HF) by two independent and blinded pathologists based on the METAVIR scoring system. Severity of fibrosis was assessed as follows: F0, no fibrosis; F1, portal fibrosis only (minimal scaring); F2, portal fibrosis with rare fibrous septa; F3, portal fibrosis with numerous fibrous septa; and F4, cirrhosis. The higher fibrosis stage was used if fibrosis stages between the two biopsies were not the same. From the 44 biopsy-proven CFLD children, fibrosis staging was as follows: F0, n = 14; F1, n = 8; F2, n = 8; F3, n = 8; and F4, n = 6. Age-and sex-matched children with CF but no signs of liver disease by clinical, biochemical, or ultrasonographic assessment at enrollment and over the 2-year duration preceding enrollment/sampling were selected as CFnoLD (n = 40). No patients with CF were on CFTR modulators at the time of enrollment in this study. A group of non-CF and non-liver-disease age-and sex-matched pediatric control patients were enrolled as the healthy control group (n = 40), while attending the hospital for minor routine procedures such as: orthopedic, plastic, otolaryngology, and burns consultations. APRI and FIB-4 scores were calculated as described (10) on CF patients with available liver biochemistries and platelet counts (CFLD, n = 36; CFnoLD, n = 36).
RNa eXtRaCtioN
Total free circulating RNA was extracted from 200 µL of serum using the plasma/serum RNA Purification Mini Kit (Norgen Biotek Corporation, Thorold, ON, Canada) following manufacturer instructions, with minor modifications. RNA extraction is described in detail in the Supporting Methods.
SMall RNa liBRaRy CoNStRUCtioN aND NgS
Small RNA libraries were constructed from an initial subset of 90 serum samples corresponding to the three study cohorts: controls (n = 30), CFnoLD (n = 30), and CFLD (n = 30). Following RNA extraction, 10 RNA samples were pooled together to create three small RNA libraries (i.e., 10 patients/library) per study cohort. This strategy, adapted from previous studies, (19, 20) maintained the precision and statistical power obtained from the sample-size calculation (see Statistical Analysis of the Materials and Methods section). Libraries were prepared using the Ion Total RNA-Seq Kit v2 protocol (Revision E; Thermo Fisher Scientific) and sequenced on the Ion Proton System (Thermo Fisher Scientific, MA, US), using the Ion PI Chip v3 following the Ion PI Hi-Q Sequencing 200 Kit protocol (Revision C; Thermo Fisher Scientific). Small RNA library construction and NGS are described in detail in the Supporting Information.
ReVeRSe tRaNSCRiptioN aND qRt-pCR ValiDatioN
Becaue of low yields of miRNA in serum and the limits of detection of traditional RNA quantification methods, a fixed RNA volume input of 4 µL for every sample was used in each reaction, a common strategy when working with circulatory miRNAs. (17, 21) Reverse transcription (RT) was performed using the miScript II RT Kit (Qiagen, Venio, The Netherlands), following the manufacturer's instructions. qRT-PCR was performed on 124 samples using the miScript SYBR Green PCR Kit (Qiagen), as suggested by the manufacturer, with 2 µL of diluted complementary DNA added in triplicate for each sample. miRNA primers were designed using the miR primer algorithm. (22) RT and qRT-PCR validation are described in detail in the Supporting Methods. miRNA primers sequences are found in Supporting Table S1 .
SeQUeNCe Data aCQUiSitioN aND aNalySiS
Sequencing data were analysed using the Torrent Suite v5.0.4 (Thermo Fisher Scientific) and mirPRo software pipeline. (23) Differential expression analysis was performed in R (v3.3.2; R Foundation for Statistical Computing, Vienna, Austria), (24) using the DESeq2 v1.15.28 package. (25) NGS sequence data acquisition and analyses are described in detail in the Supporting Methods.
qRt-pCR Data aNalySiS aND ValiDatioN oF ReFeReNCe miRNas
Quantification cycle values were determined using the CFX Manager Software v3.1 (Bio-Rad) with the linear regression setting. Relative quantities of miRNA expression were calculated using the comparative threshold count method (∆∆CT). NormFinder and geNorm algorithms were used in a subset of 30 independent samples to find the most stable expressed endogenous miRNAs. miR-93-5p, miR-20a-5p, and let-7i-5p were used as endogenous reference miRNAs. Validation of endogenous miRNA is described in detail in the Supporting Methods.
StatiStiCal aNalySiS
All statistical analyses were performed in GraphPad Prism (v7; GraphPad Software Inc., San Diego, CA) and STATA (v15; StataCorp LLC, College Station, TX), with P values <0.05 considered statistically significant. Sample-size calculation was based on a previous study, (17) using a method developed by Hart et al., (26) showing that a minimum of 10 samples per group are required to detect a fold change of 2 or greater, reading depth of 20×, 80% of power, and 5% error.
Normalized qRT-PCR data were transformed to a log 2 base scale and analyzed using one-way analysis of variance (ANOVA) and Tukey's post-hoc test. Correlation analyses were performed using Spearman rank correlations. Receiver operating characteristics (ROC) analysis was used to assess the performance of selected miRNAs to distinguish between CFnoLD and CFLD children. miRNA panel calculations to differentiate study groups were based on step-wise logistic regression using the lowest Bayesian information criterion for model selection and Liu's method to determine the optimal cutpoint. Performance of miRNA panels was evaluated using 5-fold cross-validation statistical evaluation. During the 5-fold cross-validation, the observations are randomly divided into five groups of equal sizes, using one of the groups as a validation set whereas the others are fitted into the model. Considering that the METAVIR scoring system consists of five categories, the concordance statistic (c-statistic) and Obuchowski measures were used as predictive discriminators of fibrosis staging in CFLD children; in contrast to ROC curve analysis, c-statistic and Obuchowski measure do not dichotomize the observations (more detail is described in the Supporting Methods).
Data DepoSitioN
Raw NGS data used in this study are available from the Gene Expression Omnibus under accession number GSE111754.
Results
patieNt CHaRaCteRiStiCS
For this study, sera from 124 children were collected. The number of subjects for each of the study groups included 40 controls, 40 CFnoLD, and 44 CFLD. There was no significant difference in age or sex between CFLD and CFnoLD cohorts. The CFLD group had significantly higher serum AST (P < 0.0001), ALT (P < 0.0001), γ-glutamyl transpeptidase (GGT; P < 0.0001), and alkaline phosphatase (ALP; P = 0.0003) versus CFnoLD. APRI was significantly higher in CFLD compared to CFnoLD (P < 0.0001). Whereas FIB-4 was increased in CFLD, this did not reach statistical significance (P = 0.6709). Patient characteristics are shown in Table 1 .
NgS ReVealeD a CiRCUlatoRy miRNa SigNatURe iN CFlD CHilDReN
In order to identify differentially expressed circulatory miRNAs, nine libraries were sequenced using the and differential expression analysis miR-122-5p; miR-25-3p; miR-199a-3p; miR-365a-3p; miR-18a-5p; miR-126-5p; miR-142-3p; let-7g-5p; miR-103a-3p; miR-34a-5p; and miR-484 were selected as potential biomarkers of CFLD, whereas miR-19b-3p; miR-93-5p; miR-20a-5p; let-7i-5p; let-7b-5p; let-7d-5p; miR-27a-3p; and miR-146a-5p were selected as potential endogenous reference miRNAs. An independent subset of 30 samples (n = 10/ patient cohort) were used to measure expression of potential endogenous reference miRNAs. We used geNorm and NormFinder algorithms and determined an optimal panel of miR-93-5p; miR-20a-5p; and let7i-5p to be used as endogenous reference miRNA for data normalization.
CiRCUlatoRy MiRNa SigNatURe CoNFiRMatioN By qRt-pCR
Expression of differentially expressed miRNA candidates was then confirmed in the entire cohort of 124 patients (Supporting Table S3 ). Serum levels of miR-122-5p were significantly elevated in CFLD compared to both CFnoLD (fold change [FC] = 3.1; P = 0.0015) and controls (FC = 7.5; P < 0.0001) and also in CFnoLD compared to controls (FC = 2.4; P = 0.022; Fig. 1A ). Expression levels of serum miR34a-5p were also elevated in CFLD compared to both CFnoLD and controls (FC = 2.6; P = 0.0042 and FC = 2.9; P = 0.0011, respectively; Fig. 1B) .
Similarly, circulatory miR-365a-3p was overexpressed in CFLD when compared to both CFnoLD and controls (FC = 2.2; P = 0.0002 and FC = 2.2; P = 0.0001, respectively; Fig. 1C ). In contrast, expression levels of let-7g-5p were down-regulated in CFLD compared to both CFnoLD and controls (FC = −1.8; P = 0.0034 and FC = −2.1; P = 0.0003, respectively; Fig. 1D ), whereas expression levels of miR-142-3p were elevated in CFnoLD compared to CFLD (FC = 1.6; P = 0.0047; Fig. 1E ). miR-126-5p was significantly down-regulated in CFnoLD compared to controls (FC = −1.7; P = 0.042) and increased in CFLD compared to CFnoLD; however, this did not reach statistical significance (FC = 1.7; P = 0.0549).
Serum miR-18a-5p levels were up-regulated in both CFnoLD and CFLD compared to controls (FC = 1.7; P < 0.0001 and FC = 1.7; P < 0.0001, respectively; Fig. 1F ).
CiRCUlatoRy miRNa eXpReSSioN iN CFlD F0 FiBRoSiS Stage
Fourteen children within the CFLD cohort had F0 fibrosis on dual-pass liver biopsy. Despite the absence of overt histological collagen deposition, these patients were classified as having liver disease based on clinical assessment. A subanalysis was performed on these patients with F0 fibrosis to determine whether they were distinct from children classified as CFnoLD. CFLD subjects with F0 fibrosis showed significantly higher serum levels of miR-122-5p (FC = 4.9; P = 0.001), miR-365a-3p (FC = 2.2; P = 0.009), and APRI (FC = 2.0; P < 0.0003) compared to CFnoLD children ( Fig. 2A-C) , whereas miR-142-3p (FC = −2.95; P = 0.0006) showed significantly decreased expression in F0 compared to CFnoLD (Fig. 2D) . Moreover, ROC curve analysis revealed the ability of miR-365a-3p (area under the curve [AUC] = 0.74; P = 0.007), miR-142-3p (AUC = 0.75; P = 0.006), and APRI (AUC = 0.86; P = 0.0006) to discriminate F0 from CFnoLD children.
ValiDateD MiRNa CaNDiDateS CaN DiSCRiMiNate liVeR DiSeaSe iN CHilDReN WitH CF
miR-365a-3p demonstrated the best diagnostic accuracy for liver disease (AUC = 0.74; Fig. 1 . Relative serum miRNA expression levels in CFLD, CFnoLD, and control groups. Log 2 relative expression of (A) miR-122-5p, (B) miR-34a-5p, (C) miR-365a-3p, (D) let-7g-5p, (E) miR-142-3p, and (F) miR-18a-5p. Lines represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, by ANOVA with Tukey's post-hoc test. sensitivity = 70%; specificity = 67%; P = 0.0001), whereas miR-122-5p (AUC = 0.70; sensitivity = 70%; specificity = 63%; P = 0.0001), miR-34a-5p (AUC = 0.71; sensitivity = 71%; specificity = 64.%; P = 0.0014), and let-7g-5p (AUC = 0.71; sensitivity = 70%; specificity = 65%; P = 0.0010) showed similar differential diagnostic performance (Fig. 3A) .
Next, to derive a panel of miRNAs that could diagnose liver disease in CF children, step-wise logistic regression analysis was performed using subsets of up to four miRNAs (794 models in total).
Model selection, based on Bayesian information criterion, resulted in a model including miR-365a-3p, miR-142-3p, and let-7g-5p yielding an AUC = 0.87 (P < 0.0001; Fig. 3B ). In order to assess the performance of this selected miRNA panel to diagnose liver disease in CF children, the statistical model evaluation method, 5-fold cross-validation, was performed within the same cohort of CFLD and CFnoLD children. The result of the cross-validation showed AUC = 0.79 with a sensitivity of 63% and specificity of 77% across the different validation sets.
Fig. 2.
Relative serum miRNA expression and APRI levels in CFLD F0 fibrosis versus CFnoLD. Relative expression of (A) log 2 miR-122-5p, (B) log 2 miR-365a-3p, (C) APRI, and (D) log 2 miR-142-3p. Lines represent mean ± SEM for miRNAs, or geometric mean and geometric SD for APRI. *P < 0.05; **P < 0.01; ***P < 0.001 by two-tailed t test for miRNAs and Mann-Whitney U test for APRI. F0 = no fibrosis based on METAVIR score.
aDDitioN oF apRi to miRNa paNel FoR DiFFeReNtial DiagNoSiS oF CFlD
We have previously shown the utility of APRI to detect liver disease in children with CF. (10) In our present cohort of CFLD versus CFnoLD children, APRI demonstrated an AUC = 0.80 (P < 0.0001) with a sensitivity of 79% and specificity of 80%, recapitulating the results obtained in our previous report (Fig. 3A) . (10) Logistic regression analysis combining APRI with our three-miRNA panel demonstrated a markedly improved diagnostic accuracy with an AUC = 0.91. A cut point of −5.81 was optimal for liver disease discrimination obtaining a sensitivity of 83% and specificity of 92% (see Supporting  Table S4 for logistic regression equation; Fig. 3C ). Performance evaluation of the new proposed CFLD panel using 5-fold cross-validation resulted in an AUC = 0.86 with a sensitivity of 73% and specificity of 76%. Using our three miRNA + APRI panel with a cut point of −5.81 predicted a 21 times greater odds of children with CF having CFLD, compared to the ~6 times greater odds when APRI is used alone, as described. (10) 
SeRUM miRNas ReFleCt HF SeVeRity iN CFlD
Expression of serum miRNA candidates was analyzed to assess the potential association with HF severity in CFLD (Supporting Table S5 ). Expression levels of miR-19b-3p (FC = 1.6; P = 0.0465), miR-18a-5p (FC = 1.8; P = 0.0011) and miR-142-3p (FC = 2.6; P = 0.0244) were all increased in CFLD patients with severe fibrosis/cirrhosis (F3/F4) compared to CFLD children with no fibrosis (F0). Expression of miR-142-3p was increased in CFLD with mild/moderate fibrosis (F1/F2) compared to F0 fibrosis (FC = 2.5; P = 0.026), whereas expression of miR25-3p was significantly lower (FC = −1.9; P = 0.023) in F1/F2 versus F0 fibrosis. We observed a significant positive correlation between miR-19b-3p (r s = 0.35; P = 0.021) and miR-18a-5p (r s = 0.56; P < 0.0001) and disease progression. miRNA expression levels and correlations with HF stage are depicted in Fig. 4 .
aSSoCiatioN BetWeeN SeRUM miR-18a-5p leVelS aND HF Stage iN CFlD
From the validated differentially expressed miRNAs between fibrosis stages, only miR-18a-5p demonstrated potential for discriminating severity of liver disease in CF children (Supporting Table S5 ). ROC curve analysis to determine the ability of miR-18a-5p to distinguish liver disease severity within CFLD yielded the following: F0 versus any fibrosis/cirrhosis (F1-F4) exhibited an AUC = 0.78 (P = 0.003; sensitivity = 76%; specificity = 64%), whereas F0-F1 versus F2-F4 showed an AUC = 0.76 (P = 0.003; sensitivity = 86%; specificity = 59%) and F0-F2 versus F3-F4 demonstrated an AUC = 0.82 (P = 0.004; sensitivity = 92%; specificity = 73%; Fig. 5 ). In our model, miR-18a-5p demonstrated a c-statistic = 0.74, whereas APRI had a c-statistic = 0.64; in addition, miR-18a-5p had an Obuchowski measure = 0.74, whereas APRI had an Obuchowski measure = 0.59 (Table 2) .
Step-wise ordinal logistic regression analysis was performed to evaluate the performance of selected miRNAs + APRI in predicting CFLD severity; however, only miR-18a-5p demonstrated a statistically significant result (P = 0.001). In our model, one unit of increased log2 relative expression is associated with 7-fold increased odds of having advanced fibrosis. When APRI was added to miR-18a-5p as a predictor of CFLD severity in combined logistic regression, there was no improvement in its performance with an Obuchowski measure of 0.71 for both miR-18a-5p alone and combined with APRI.
SeRUM miRNa eXpReSSioN leVelS CoRRelate WitH liVeR eNZyMeS
In CFnoLD children, AST and GGT showed significant positive correlation with miR-365a-3p and miR-34a-5p, respectively, whereas significant negative correlations were observed between GGT with miR19b-3p, miR-103a-3p, and miR-484; and ALP with miR-34a-5p (Supporting Table S6 ). In CFLD children, significant positive correlations were observed for AST with miR-34a-5p; ALT with miR-122-5p, miR-34a-5p, and miR-19b-3p; and ALP with miR19b-3p (Supporting Table S6 ). Similar correlations were observed between APRI and these miRNAs, which is expected given that APRI is based on AST and platelet count. In fact, when compared to APRI as a biomarker for liver disease progression, miR365a-3p showed a positive correlation in CFnoLD children, whereas miR-34a-5p was positively correlated in CFLD patients (Supporting Table S6 ).
Discussion
Prevalence of liver disease in children with CF ranges between 20% and 40%, (27, 28) depending on definitions and tools used. The reasons why only select CF patients develop clinically significant liver damage remain unclear. Lack of a uniform clinical definition hinders the diagnosis of CFLD in children because it relies on nonspecific clinical, biochemical, and imaging assessments. We have previously demonstrated the utility of a variety of different serum biomarkers as noninvasive alternatives to distinguish between CFnoLD and CFLD in children, (10, 29) although the relative diagnostic accuracy of these modalities are less than ideal. We have also demonstrated the potential of circulatory miRNA for discriminating liver disease in CF children and disease severity using a limited miRNA array screen. (17) In the present study, we used serum miRNA-Seq with PCR validation to assess unknown and known miRNAs in children with liver-biopsy-validated CFLD to demonstrate differential miRNA expression compared to children with CFnoLD and healthy controls, as well as to assess utility in predicting HF severity.
In this study, following miRNA-Seq, qRT-PCR validation on serum of 124 children confirmed increased expression of miR-122-5p, miR-34a-5p, and miR-365a-3p in CFLD versus CFnoLD whereas let-7g-5p and miR-142-3p expression was decreased. The most abundant miRNA in the liver is miR-122, which accounts for more than half of the total hepatic miRNA content. (31) Multiple studies have reported increased circulatory levels of miR-122 in pediatric CLDs such as biliary atresia, CFLD, nonalcoholic fatty liver disease (NAFLD), and hepatitis B. (17, (32) (33) (34) Our study shows increased circulatory miR-122 levels in children with CFLD when compared to both CFnoLD and healthy controls. We also found overexpression of miR-122 in CFnoLD compared to healthy controls. It is possible that altered circulatory miR-122 expression is an early marker of liver injury and thus detected before the existing clinical modalities used in this study to identify children with CFLD. Autopsy studies have reported that up to 70% of CF patients show focal biliary cirrhosis, (6) which suggests that some of the CFnoLD children in our group may have liver damage that may manifest as an overexpression of miR-122 before its detection by the traditional diagnostic methods. We also found miR34a-5p and miR-365a-3p to be up-regulated in serum of CFLD compared to CFnoLD children. Increased serum levels of miR-34a have been reported in CLDs such as hepatitis C and NAFLD. (35, 36) miR-34a has been associated with liver regeneration, having a direct repressor effect on hepatocyte proliferation and senescence in alcoholic liver injury and in animal models of partial hepatectomy. (37, 38) Moreover, a significant increase of miR-34a expression has been reported in liver disease, including cholestasis. Based on our previous studies, (40) we have proposed a role for the hydrophobic bile acid, taurocholate, in the abnormal development of bile ducts, a process known as the ductular reaction, in CFLD. (41) Key components of the Notch signaling pathway, such as Notch1, Notch2, and Jagged1, are direct targets of miR-34a. (42) There is supporting evidence that hepatic stellate cells (HSCs) and macrophages can influence the differentiation of liver progenitor cells into reactive biliary cells and bile ducts by the Notch pathway, (43) therefore suggesting a potential role of miR-34a in the manifestation of CFLD. A potential role of miR-365 has been implicated in pediatric CLD, including biliary atresia, (44) and increased levels of circulating miR-365a-3p have been found in the plasma of children with hepatitis B, suggesting its potential as a biomarker for disease progression. (33, 45) However, further mechanistic studies are required to fully elucidate the role of miR-34a-5p and miR365a-3p in the pathogenesis of these pediatric liver diseases.
We also found a decreased expression of serum let-7g-5p and miR-142-3p in CFLD compared to CFnoLD children. Both let-7g-5p and miR-142-3p expression are down-regulated in hepatocellular carcinoma (HCC) (46, 47) and are involved in suppressing HCC cell migration, motility, and invasion. (46, 48) Downregulated miR-142-3p has also been found in activated HSCs controlling cell viability and cell growth by targeting transforming growth factor β receptor 1. (49) Based on the functions that these miRNAs play in HCC and in HSCs, it is possible that their decreased expression in CFLD children may play a role in preventing fibrosis. Functional studies are required to establish the origin and potential role that these differentially expressed miRNAs may play in CFLD and in the development of fibrosis.
We have highlighted serum miR-365a-3p, miR-34a-5p, and let-7g-5p, which individually demonstrated moderate clinical utility for liver disease detection in CF with areas under the ROC curve (AUROCs) ranging between 0.71 and 0.74 (Supporting Table S3 ). However, using step-wise logistic regression analysis, we identified a miRNA panel consisting of miR-365a-3p, miR-142-3p, and let-7g-5p with the ability to discriminate liver disease in CF children with an AUC = 0.87. Recently, we reported that APRI can differentiate liver disease in CF children with an AUC = 0.75 and severe CFLD (F3-F4) from mild-to-moderate CFLD (F0-F2) with an AUC = 0.81. (10) When APRI was combined with our proposed miRNA panel, we observed a marked improvement in discriminating CFLD from CFnoLD with an AUC = 0.91. Performance evaluation of the selected miRNA panel using 5-fold cross-validation resulted in an AUC = 0.79 for our three-miRNA panel and an AUC = 0.86 when our miRNA panel was combined with APRI, thus validating its significant discriminatory capacity. Our proposed threemiRNA + APRI panel outperforms APRI alone in predicting CFLD even in 5-fold cross-validation evaluation. This study represents one of the largest biopsy-proven CFLD cohorts with internal cross-validation methodology that confirms the clinical utility of our combined three-miRNA + APRI biomarker panel.
There is a clinical need for the continuous assessment of CFLD to monitor disease progression in order to provide anticipatory guidance or identify patients in need of future liver transplantation. In this study, we found significant differences in expression of miR19b-3p, miR-25-3p, miR-18a-5p, and miR-142-3p between varying METAVIR fibrosis stages. Moreover, we identified a significant positive correlation between miR-19b-3p and miR-18a-5p with fibrosis advancement. Specifically, miR-18a-5p discriminated severe fibrosis (F3-F4) from mild-to-moderate fibrosis (F0-F2; Supporting Table S5 ). miR-18-5p was able to discriminate liver disease severity in CFLD children when comparing F0 versus F1-F4 (AUC = 0.78), F0-F1 versus F2-4 (AUC = 0.76), and F0-F2 versus F3-F4 (AUC = 0.82). These data suggest that miR18a-5p was able to significantly differentiate CFLD severity in all three cases, and its diagnostic performance was better than our previously published result for APRI in stratifying disease progression (Table 2) . To assess the discriminatory accuracy of predicting CFLD severity, these results were further evaluated using the Obuchowski measure as suggested by Lambert et al. (50) In our model, miR-18a-5p produced an Obuchowski measure of 0.74, which was superior to APRI with an Obuchowski measure of 0.59. Lambert et al. suggest using penalties proportional to the difference in METAVIR units between stages. Applying this penalty scheme, miR-18a-5p remains superior to APRI in discriminating liver disease severity with an Obuchowski measure of 0.79 and 0.68, respectively (Supporting Table S5 ).
The most appropriate case definition of CFLD remains a topic of ongoing discussion in pediatric hepatology. Our study used the definitions and guidelines recommended by the European Society for Paediatric Gastroenterology, Hepatology and Nutrition to categorize CFLD. These guidelines state that CFLD should be considered when at least two of the following conditions are present: abnormal physical examination (hepatomegaly ± splenomegaly), persistent abnormalities of liver function tests and ultrasonographic evidence of liver involvement (including increased and/or heterogeneous echogenicity, nodularity,) or portal hypertension. (18) By using these criteria, we decreased the risk of ignoring important aspects of the disease as well as over interpreting others such as elevation of serum transaminases, which are relatively common among the CF population. Others have proposed that CFLD should be defined as the presence of cirrhosis/portal hypertension, or intermittent elevation of liver transaminases, steatosis, fibrosis, cholangiopathy, or ultrasound abnormalities. (30) Both definitions use nonspecific diagnostic criteria and prioritize advanced liver disease/cirrhosis against early manifestations of the disease or fibrogenic processes that could potentially lead to misclassification. The case definition in our cohort for CFLD should be considered when assessing the clinical utility of our findings. However, we believe our observations are robust for important reasons. First, we performed dual-pass liver biopsy to stage HF in all children classified as CFLD, as reported. (7) Second, fibrosis staging revealed 14 children without histological evidence of fibrosis (F0 fibrosis), but with a serum miRNA profile distinct from CFnoLD. In a subanalysis, we showed that serum miR-122-5p, miR-365a-3p, and APRI were all significantly increased, whereas miR-142-3p was significantly decreased in CFLD F0 fibrosis when compared to CFnoLD, which mirrored the observations for the collective CFLD cohort. Thus, these findings suggest that subjects classified as CFLD were correctly classified, even in the absence of overt histological fibrosis.
In summary, these serum miRNA biomarkers, when used in combination with the free and readily available APRI index, are able to predict CFLD and assess disease severity with an excellent diagnostic accuracy compared to the current gold standard of liver biopsy. Here, we report that a combination of circulatory levels of miR-365a-3p, miR-142-3p, and let-7g-5p, together with APRI, is capable of early diagnosis of CFLD. Furthermore, expression of miR-18a-5p was able to stratify disease severity in children with CFLD. Although our proposed panel requires further validation, it may provide vital information to assess prognosis and disease severity. In conclusion, our proposed three-miRNA + APRI panel has the potential to identify and stratify CFLD especially at an early stage where timely intervention is critical to improve patient outcomes. Furthermore, functional studies on the role that these miRNAs play in the development of CFLD have the potential to provide future therapeutic strategies and may offer further insights into CFLD pathogenesis.
